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Abstract
First described in 1972 by Benveniste and colleagues, platelet-activating factor (PAF) remains one 
of the potent phospholipid known to date. The role of PAF produced enzymatically in mediating 
diverse biological and pathophysiological processes including inflammatory and allergic diseases 
and cancers in response to various stimuli has been extensively studied. However, little is known 
about the role of non-enzymatically-generated PAF-like lipids produced in response to pro-
oxidative stressors, particularly in modulating the host immune responses to tumor immunity, 
which is the focus of this review.
INTRODUCTION
PAF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) is cellular membrane derived 
phospholipids that mediate its effects via binding to a seven transmembrane G-protein 
coupled receptor, the PAF-receptor (PAF-R). The expression of the PAF-R has been 
identified on various immune and non-immune cell types including epithelial, endothelial 
and cancer cells [1–3]. Enzymatic PAF synthesis is a tightly regulated process that utilizes 
two different pathways (de novo and remodeling) [4]. In contrast, the exposure to ubiquitous 
pro-oxidative stressors capable of producing reactive oxygen species (ROS) generate non-
enzymatically cleaved oxidized glycerophosphocholines (Ox-GPCs) directly from parent 
membrane glycerophosphocholines (GPCs) that exhibit PAF-R agonistic activity [5–8]. 
These pro-oxidative stressors include environmental exposures such as ultraviolet B (UVB) 
radiation, aryl hydrocarbons from jet fuel to cigarette smoke. Moreover, clinically relevant 
chemotherapeutic agents, and radiation and photodynamic therapies can also generate Ox-
GPCs [5–12]. The activity of both enzymatic PAF as well as Ox-GPCs is thought to be 
regulated by the major PAF-metabolizing enzyme, serum PAF-acetyl hydrolase (PAF-AH) 
[2].
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PAF and tumor immunity
Several research groups including ours have investigated the role of Ox-GPCs/PAF-R 
agonists in modulating cutaneous inflammation and host immunity [5–12]. To emphasize, 
we and others have demonstrated that Ox-GPCs generated via pro-oxidative stressors 
including UVB and cigarette smoke exposure mediate systemic immunosuppression via a 
mechanism that involves PAF-R dependent induction of cyclooxygenase type 2 (COX-2) and 
related prostaglandins and eicosanoids, immunosuppressive cytokine, interleukin 10 (IL-10) 
and tumor growth factor beta (TGFβ) [7–9,13]. Of significance, our recent studies have 
demonstrated that these Ox-GPCs/PAF-R agonists mediated systemic immunosuppression 
augment the growth of experimental murine B16F10 melanoma tumors. This latter process 
requires host stromal-PAF-R dependent modulation of tumor microenvironment associated 
suppressive immunophenotype, regulatory T cells (Tregs) [13]. Of importance, PAF-R 
signaling has been implicated in promoting angiogenesis and metastasis via its direct effects 
on tumor cell PAF-R [14]. Notably, our studies have shown that systemic PAF-R agonists 
augments the growth of PAF-R negative experimental murine Lewis Lung Cancer (LLC1) 
growth and metastasis via activating host cell-PAF-R rather tumor cell-PAF-R [15]. These 
studies indicate that the implications of Ox-GPCs effects on tumor immunity are not limited 
to melanoma but can also be applied to lung cancer as wells as its metastatic ability.
The induction of the PAF-R expression on melanoma cells has been shown to be modulated 
by chemotherapy and this act to mediate a prosurvival response of tumor cells by 
chemotherapy and is attenuated by PAF-R antagonists [16]. However, whether or not 
chemotherapy-mediated effects are via the modulation of the host immune responses is not 
clear. In our recently completed studies, we demonstrated that treatments with 
chemotherapeutic agents to murine or human melanoma cells lines in vitro or in vivo 
generate several novel Ox-CPCs with the PAF-R agonists activity in a process blocked by 
antioxidants. The expression of the PAF-R in tumor cells resulted in enhanced production of 
Ox-GPCs compared to the PAF-R-deficient tumor cells (studies submitted for publication). 
The dual tumor model, where implantation of two tumors in PAF-R expressing and deficient 
syngeneic mice followed by intratumoral treatment of one tumor with the chemotherapeutic 
agents and measuring the growth of other (secondary) tumor has allowed us the direct 
assessment of the host anti-tumor immune responses to chemotherapy in the modulation of 
melanoma tumor growth. We demonstrated that chemotherapy mediated generation of Ox-
GPCs augments the growth of secondary tumors in a PAF-R dependent manner. These 
effects are blocked by the antioxidants, COX-2 inhibitors and depleting antibodies against 
Tregs. Importantly, several novel Ox-GPCs were detected in the perfusates of melanoma 
patients undergoing isolated limb chemoperfusion with melphalan chemotherapy. These 
findings indicate that chemotherapeutic agents due to their ability to act as potent pro-
oxidative stressors can modulate the growth of melanoma tumors via affecting the adaptive 
arm of the host immune system mediated through the generation of non-enzymatic oxidized 
PAF-R agonists.
Myeloid derived suppressor cells (MDSCs), an immature population of myeloid progenitor 
cells have been shown to exert potent suppressive activity towards the innate and adaptive 
arm of the host immune system and promote carcinogenesis. Our ongoing studies have 
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discovered that MDSCs mediate PAF-R agonists induced systemic immunosuppressive 
effects. Nevertheless, the cross talk between MDSCs and Tregs in mediating PAF-R agonists 
induced augmentation of cancer growths are under investigation in our laboratory. Since, 
tumor associated suppressive type 2 macrophages (M2) share the common profile with 
MDSCs, particularly the activation markers such as arginase 1, inducible nitric oxide 
synthetase (iNOS), IL-10, mgl1, fizz1 and ccl2, the clear demonstration of whether M2 
macrophages are being recruited by MDSCs into tumor microenvironment will further shed 
a light into the mechanisms of PAF-R agonists mediated tumor growth.
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